ADVERTISEMENT

TGCT

Pexidartinib Yields Tumor Regression in Patients with TGCT

11/22/2021

Pexidartinib demonstrated durable tumor regression, with manageable safety, in patients with TGCT.

Pexidartinib demonstrated durable tumor regression, with manageable safety, in patients with TGCT.

Pexidartinib demonstrated...

11/22/2021

Oncology

Test Your Knowledge

Quiz: Does Vimseltinib Exhibit Antitumor Activity in TGCT?

09/30/2021

True or false: Results from a study presented at the 2021 ESMO Congress showed Vimseltinib did not yield promising antitumor activity in tenosynovial giant cell tumor (TGCT).

True or false: Results from a study presented at the 2021 ESMO Congress showed Vimseltinib did not yield promising antitumor activity in tenosynovial giant cell tumor (TGCT).

True or false: Results from a...

09/30/2021

Oncology

Vimseltinib Demonstrates Promising Antitumor Activity in TGCT

09/17/2021

According to data presented at the 2021 Virtual ESMO Congress, vimseltinib was well tolerated and demonstrated antitumor activity in patients with TGCT.

According to data presented at the 2021 Virtual ESMO Congress, vimseltinib was well tolerated and demonstrated antitumor activity in patients with TGCT.

According to data presented at...

09/17/2021

Oncology

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Advertisement

Advertisement

Advertisement

Upcoming Events

November 8 ⁠–⁠ November 10

Dermatology Week

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

See Full Calendar

Advertisement

Advertisement